GLP-1 drugs in the study included semaglutide, sold by Novo Nordisk as Wegovy and Ozempic
But until now, there hasnt been any data from large epidemiologic studies. Results showed use of GLP-1 agonists compared with bupropion-naltrexone correlated with a 9.09 (95% CI, 1.25-66), 4.22 (95% CI, 1.02-17.4) and 3.67 (95% CI, 1.15-11.9) times higher risk for pancreatitis, bowel obstruction and gastroparesis, respectively
2.The picture is the experimental effect, the actual effect varies from person to person
Short-term usea day or two for acute paincarries lower risk than ongoing doses
Add to natural cleaning products for a personalized fragrance boost
Additionally, appetite suppressants are not a substitute for adopting a healthy lifestyle, including a balanced diet and regular physical activity